Revance Therapeutics (RVNC)
(Real Time Quote from BATS)
$3.04 USD
+0.13 (4.47%)
Updated Jun 5, 2024 01:36 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Revance Therapeutics, Inc. [RVNC]
Reports for Purchase
Showing records 41 - 58 ( 58 total )
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Mylan Says "Yes" to Botox Biosimilar Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Revance Stays Active in Business Development With HintMD Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Catalysts on Track Despite Covid-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Challenging Backdrop Warrants Tempering of Expectations Through ''21; Reiterate Buy,
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Revance Gets Ready for Lift off; Raise PT to $28, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Final Program for Our Third Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Evolus and Revance Stand to Gain From Likely Disruption Caused by AbbVie Acquiring Allergan
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BLA Delayed Until Fall; Reiterate Buy; Target Goes to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Evolus, Inc. and Revance Therapeutics: BoNT-A Market Update After the American Academy of Dermatology Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Slides Reviewing Initiations on Dermatology and Endocrinology
Provider: H.C. Wainwright & Co., Inc.
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cordially invites you to a Coverage Launch Teach-In
Provider: H.C. Wainwright & Co., Inc.
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Duration That Counts; Initiate at Buy With a $25 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Launching Coverage
Provider: H.C. Wainwright & Co., Inc.